InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III study CONCLUDE as a novel treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.
View Top Employees from InDex Pharmaceuticals ABWebsite | http://www.indexpharma.com |
Revenue | $6 million |
Funding | $31.3 million |
Employees | 22 (17 on RocketReach) |
Founded | 2000 |
Address | Berzelius väg 13, Solna, Stockholm County 171 65, SE |
Phone | +46 8 122 038 50 |
Fax | +46 8 508 847 39 |
Technologies |
JavaScript,
HTML,
Twitter
+11 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Biopharma, Manufacturing, Biotechnology, Health Care, Science and Engineering, Medical |
Web Rank | 7 Million |
Keywords | Index Pharmaceuticals |
SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 2834 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 541711 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies |
Looking for a particular InDex Pharmaceuticals AB employee's phone or email?
The InDex Pharmaceuticals AB annual revenue was $6 million in 2024.
Thomas Knittel is the Chief Medical Officer of InDex Pharmaceuticals AB.
17 people are employed at InDex Pharmaceuticals AB.
InDex Pharmaceuticals AB is based in Solna, Stockholm County.
The NAICS codes for InDex Pharmaceuticals AB are [54171, 541711, 5417, 541, 54].
The SIC codes for InDex Pharmaceuticals AB are [283, 28, 2834].